donepezil has been researched along with CADASILM in 2 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
CADASILM: A subvariety of CADASIL characterized by the high frequency of MIGRAINE. The acronym stands for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts, Leukoencephalopathy, and Migraine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment." | 9.13 | Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. ( Chabriat, HS; Dichgans, M; Markus, HS; Moline, M; Posner, H; Salloway, S; Verkkoniemi, A; Wang, Q, 2008) |
| "Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment." | 5.13 | Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. ( Chabriat, HS; Dichgans, M; Markus, HS; Moline, M; Posner, H; Salloway, S; Verkkoniemi, A; Wang, Q, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schneider, LS | 1 |
| Dichgans, M | 1 |
| Markus, HS | 1 |
| Salloway, S | 1 |
| Verkkoniemi, A | 1 |
| Moline, M | 1 |
| Wang, Q | 1 |
| Posner, H | 1 |
| Chabriat, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment[NCT00103948] | Phase 2 | 165 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for donepezil and CADASILM
| Article | Year |
|---|---|
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Topics: Adult; Aged; CADASIL; Cognition Disorders; Confidence Intervals; Donepezil; Double-Blind Method; Fem | 2008 |
1 other study available for donepezil and CADASILM
| Article | Year |
|---|---|
Does donepezil improve executive function in patients with CADASIL?
Topics: CADASIL; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Problem Solving | 2008 |